Immunological Tolerance of the Human Fetus

 

 Buy Article Permissions and Reprints

ABSTRACT

Why is the fetus not rejected as foreign tissue? The maternal and fetal immune systems temporarily coexist; both are precisely tuned to detect and reject foreign invasion and yet somehow achieve a symbiotic relationship. This mutual state of tolerance is obviously critical for carrying pregnancy to full term. Two active arms of the immune system maintain protection of the host: the first of these involves a humoral immune system in which foreign tissue invokes an antibody response by recognition of antigenic surfaces by the B-cell, the second arm involves cell-mediated immunity in which T-cells and natural killer (NK) cells seek out and destroy foreign tissue. Several mechanisms are thought to invoke the immune tolerance of the fetus. These include: absence of major histocompatibility complex (MHC)-I antigens, presence of unique human lymphocyte antigen (HLA) surface molecules, nonspecific reduction of systemic immunoreactivity, possible role of blocking antibody, expressions of complement regulatory proteins, and factors of locally reduced immunoreactivity. Ultimately, developing regimens to control these elements in the clinical setting may help us overcome preterm labor, infertility, and preeclampsia. Available evidence regarding immune tolerance of the human fetus, integrated into a workable model, and focused at an overview level are systematically reviewed in this article.

REFERENCES

• 1 Hunt J S. Immunobiology of pregnancy.  Curr Opin Immunol . 1992;  4 591-596
  CrossrefPubMedGoogle Scholar
• 2 Johnson P. Immunobiology of the human placental trophoblast.  Exp Clin Immunogenet . 1993;  10 118-122
  PubMedGoogle Scholar
• 3 Enders A C. Trophoblast differentiation during the transition from trophoblastic plate to lacunar stage of implantation in the rhesus monkey and human.  Am J Anat . 1989;  186 85-98
  CrossrefPubMedGoogle Scholar
• 4 Rajewsky K. Clonal selection and learning in the antibody system.  Nature . 1996;  381 751-758
  CrossrefPubMedGoogle Scholar
• 5 Bulmer J N. Immune aspects of pathology of the placental bed contributing to placental pathology.  Baillieres Clin Obstet Gynaecol . 1992;  6 461-488
  PubMedGoogle Scholar
• 6 Koopmann J O, Hammerling G J, Momburg F. Generation, intracellular transport and loading of peptides associated with MHC class I molecules.  Curr Opin Immunol . 1997;  9 80-88
  CrossrefPubMedGoogle Scholar
• 7 Pieters J. MHC Class II compartments: specialized organelles of the endocytic pathway in antigen presenting cells.  Biol Chem . 1997;  378 751-758
  PubMedGoogle Scholar
• 8 Kiessling R, Kein E, Wigzell H. ``Natural'' killer cells in the mouse I: cytotoxic cells with specificity for mouse Moloney leukemia cells: specificity and distribution according to genotype.  Eur J Immunol . 1975;  5 112-117
  PubMedGoogle Scholar
• 9 King A, Burrows T, Verma S, Loke Y W. Human uterine lymphocytes.  Hum Reprod Update . 1998;  4 480-485
  CrossrefPubMedGoogle Scholar
• 10 Starkey P M. Natural killer cells/large granular lymphocytes in pregnancy. In: Lewis CE, McGee JO, eds. The Natural Killer Cell New York: Oxford University Press 1992: 205-240
  Google Scholar
• 11 Chao K H. The expression of killer cell inhibitory receptors on natural killer cells and activation status of CD4+ and CD8+ T cells in the decidua of normal and abnormal early pregnancies.  Hum Immunol . 1999;  60 791-797
  CrossrefPubMedGoogle Scholar
• 12 Roberts K, Lotze M T, Rosenberg S A. Separation and functional studies of the human lymphokine-activated killer cell.  Cancer Res . 1987;  47 4366-4371
  PubMedGoogle Scholar
• 13 Biron C A, Nguyen K B, Pien G C, Cousens L P, Salazar-Mather T P. Natural killer cells in antiviral defense: function and regulation by innate cytokines.  Annu Rev Immunol . 1999;  17 189-220
  CrossrefPubMedGoogle Scholar
• 14 Unanue E R. Inter-relationship among macrophages, natural killer cells and neutrophils in early stages of Listeria resistance.  Curr Opin Immunol . 1997;  17 189-220
  PubMedGoogle Scholar
• 15 Seaman W E. Natural killer cells and natural killer T cells.  Arthritis Rheum . 2000;  43 1204-1217
  CrossrefPubMedGoogle Scholar
• 16 Kerr J FR, Wyllie A H, Curie A R. Apoptosis: a basic biological phenomenon with widespread implications in tissue kinetics.  Br J Cancer . 1972;  26 239-257
  CrossrefPubMedGoogle Scholar
• 17 Wyllie A H, Kerr J FR, Currie A R. Cell death: the significance of apoptosis.  Int Rev Cytol . 1980;  68 251-306
  PubMedGoogle Scholar
• 18 Ellis R E, Yuan J, Horvitz H R. Mechanisms and functions of cell death.  Ann Rev Cell Biol . 1991;  7 663-698
  PubMedGoogle Scholar
• 19 Levy R. To be, or not to be, that is the question: apoptosis in human trophoblast.  Placenta . 2000;  21 1-13
  CrossrefPubMedGoogle Scholar
• 20 DeFougerolles A R, Baines M G. Modulation of the natural killer cell activity in pregnant mice alters the spontaneous abortion rate.  J Reprod Immunol . 1987;  11 147-153
  PubMedGoogle Scholar
• 21 Aoki K. Preconceptional natural-killer-cell activity as a predictor of miscarriage.  Lancet . 1995;  345 1340-1342
  CrossrefPubMedGoogle Scholar
• 22 Guimond M, Wang B, Croy B A. Immune competence involving the natural killer cell lineage promotes placental growth.  Placenta . 1999;  20 441-450
  CrossrefPubMedGoogle Scholar
• 23 Head J R, Drake B L, Zukerman F A. Major histocompatibility antigens on trophoblast and their regulation: implications in the maternal-fetal relationship.  Am J Reprod Immunol Microbiol . 1987;  15 12-18
  PubMedGoogle Scholar
• 24 Billington W D. The normal fetomaternal immune relationship.  Baillieres Clin Obstet Gynaecol . 1992;  6 417-437
  PubMedGoogle Scholar
• 25 Karimu A L, Burton G J. Significance of changes in fetal perfusion pressure to factors controlling angiogenisis in the human term placenta.  J Reprod Fertil . 1994;  102 447-450
  PubMedGoogle Scholar
• 26 Hunt J S, Andrews G K, Wood G W. Normal trophoblast resists induction of class I HLA.  J Immunol . 1987;  138 2481-2487
  PubMedGoogle Scholar
• 27 Hara N, Fujii T, Yamashita T. Altered expression of human leukocyte antigen G (HLA-G) on extravillous trophoblasts in preeclampsia: immunohistochemical demonstration with anti-HLA-G specific antibody ``87G'' and anti-cytokeratin antibody ``CAM5.2''.  Am J Reprod Immunol . 1996;  36 349-358
  PubMedGoogle Scholar
• 28 Athanassakkis I, Aifantis Y, Makrygiannakis A. Placental tissue from human miscarriage expresses Class II HLA-DR antigens.  Am J Reprod Immunol . 1995;  34 281-287
  PubMedGoogle Scholar
• 29 Fernandez N. A critical review of the role of the major histocompatibility complex in fertilization, preimplantation development and feto-maternal interactions.  Hum Reprod Update . 1999;  5 234-248
  CrossrefPubMedGoogle Scholar
• 30 Janeway C A, Travers P. Immunobiology: The Immune System in Health and Disease.  2nd ed. New York: Garland Publishing 1996: 11-33
  Google Scholar
• 31 Bainbridge D R. Little evidence of HLA-G mRNA polymorphism in Caucasian or Afro-Caribbean populations.  J Immunol . 1999;  163 2023-2027
  PubMedGoogle Scholar
• 32 Muntz C. Peptide presentation and NK inhibition by HLA-G.  J Reprod Immunol . 1999;  43 139-155
  PubMedGoogle Scholar
• 33 Kovats S, Main E K, Librach C, Stubblebine M, Fisher S J, DeMars R. A class I antigen, HLA-G, expressed in human trophoblasts.  Science . 1990;  248 220-223
  CrossrefPubMedGoogle Scholar
• 34 Houlihan J M, Biro P A, Fergar-Payne A, Simpson K L, Holmes C H. Evidence for the expression of non-HLA-A, -B, -C class I genes in the fetal liver.  J Immunol . 1992;  149 668-675
  PubMedGoogle Scholar
• 35 Proll J. First trimester human endovascular trophoblast cells express both HLA-C and HLA-G.  Am J Reprod Immunol . 1999;  42 30-36
  PubMedGoogle Scholar
• 36 Ellis S A, Palmer M S, McMicheal A J. Human trophoblast and the choriocarcinoma cell line BeWo expresses a truncated HLA class I molecule.  J Immunol . 1990;  144 731-735
  PubMedGoogle Scholar
• 37 Adrian C F, Moreau P, Riteau B. HLA-G expression in human melanoma cells: protection from NK cytolysis.  J Reprod Immunol . 1999;  43 183-193
  PubMedGoogle Scholar
• 38 King A, Loke Y W. On the nature and function of uterine granular lymphocytes.  Immunol Today . 1991;  12 432-435
  CrossrefPubMedGoogle Scholar
• 39 Hamai Y. The expression of human leukocyte antigen-G on trophoblasts abolishes the growth-suppressing effect of interleukin-2 towards them.  Am J Reprod Immunol . 1999;  41 153-158
  PubMedGoogle Scholar
• 40 Ljunggren G, Karre K. In search of the missing self-MHC molecules and NK cell recognition.  Immunol Today . 1990;  11 237-244
  CrossrefPubMedGoogle Scholar
• 41 Goldman-Wohl D S. HLA-G expression in extravillous trophoblasts is an intrinsic property of cell differentiation: a lesson learned from ectopic pregnancies.  Mol Hum Reprod . 2000;  6 535-540
  CrossrefPubMedGoogle Scholar
• 42 Kovats S. A class I antigen, HLA-G, expressed in human trophoblasts.  Science . 1990;  248 220-223
  CrossrefPubMedGoogle Scholar
• 43 Rajagopalan S. A human histocompatibility leukocyte antigen (HLA)-G-specific receptor expressed on all natural killer cells.  J Exp Med . 1999;  189 1093-1100
  CrossrefPubMedGoogle Scholar
• 44 Bainbridge D R. The short forms of HLA-G are unlikely to play a role in pregnancy because they are not expressed at the cell surface.  J Reprod Immunol . 2000;  47 1-16
  CrossrefPubMedGoogle Scholar
• 45 Pfeiffer K A. Soluble HLA levels in early pregnancy after in vitro fertilization.  Hum Immunol . 2000;  61 559-564
  CrossrefPubMedGoogle Scholar
• 46 Goldman-Wohl D S. Lack of human leukocyte antigen-G expression in extravillous trophoblasts is associated with pre-eclampsia.  Mol Hum Reprod . 2000;  6 88-95
  CrossrefPubMedGoogle Scholar
• 47 Lawrence R, Church J A, Richards W, Borzy M. Immunological mechanisms in the maintenance of pregnancy.  Ann Allergy . 1980;  44 166-173
  PubMedGoogle Scholar
• 48 Brabin B J. Epidemiology of infection in pregnancy.  Rev Infect Dis . 1985;  7 579-603
  PubMedGoogle Scholar
• 49 Glassman A B, Bennet C E, Cristopher J B, Self S. Immunity during pregnancy: lymphocyte subpopulation and mitogen responsiveness.  Ann Clin Lab Sci . 1985;  15 357-362
  PubMedGoogle Scholar
• 50 Piccinni M P. Role of hormone-controlled Th1- and Th2-type cytokines in successful pregnancy.  J Neuroimmunol . 2000;  109 30-33
  CrossrefPubMedGoogle Scholar
• 51 Wegmann T G, Lin H, Guilbert L J, Mosmann T R. Bidirectional cytokine interactions in the maternal-fetal relationship: is successful pregnancy a Th2 phenomenon?.  Immunol Today . 1994;  14 353-356
  PubMedGoogle Scholar
• 52 Raghupathy R. Maternal anti-placental cell-mediated reactivity and spontaneous abortions.  Am J Reprod Immunol . 1987;  37 478-484
  PubMedGoogle Scholar
• 53 Mossmann T R, Sad S, Krishnan L. Differentiation of subsets of CD4+ and CD8+ T cells. In: T Cell Subsets in Infectious and Autoimmune Diseases New York: John Wiley and Sons 1995: 42-50
  Google Scholar
• 54 Silver R M, Branch D W. The immunology of pregnancy. In: Creasy RK, Resnik R, eds. Maternal-Fetal Medicine 4th ed. Philadelphia: WB Saunders 1999: 72-89
  Google Scholar
• 55 Nigro G. Low levels of natural killer cells in pregnant women transmitting Toxoplasma gondii.  Prenat Diagn . 1999;  19 401-404
  CrossrefPubMedGoogle Scholar
• 56 Sell S. Immunology, Immunopathology and Immunity.  4th ed. New York: Elsivier 1987: 490-510
  Google Scholar
• 57 Burke J, Johansen K. The formation of HLA antibodies in pregnancy, the antigenicity of aborted and term fetuses.  J Obstet Gynaecol Br Commonwealth . 1974;  81 222-228
  PubMedGoogle Scholar
• 58 Kuby J. Immunology.  New York: WH Freeman 1992: 522-523
  Google Scholar
• 59 Sargent I. Maternal and fetal immune responses during pregnancy.  Exp Clin Immunogenet . 1993;  10 85-102
  PubMedGoogle Scholar
• 60 Reed E, Beer A E, Hutcherson H. The alloantibody response of pregnant women and its suppression by soluble HLA antigens and anti-idiotypic antibodies.  J Reprod Immunol . 1991;  20 115-135
  PubMedGoogle Scholar
• 61 Unander A M, Norberg R, Arfors L. Opinions on treatment of women with habitual abortion based on investigations for blocking antibody and autoantibodies.  Am J Reprod Immunol . 1991;  26 32-37
  PubMedGoogle Scholar
• 62 Beer A E, Semprini A E, Zhu X. Pregnancy outcomes in human couples with recurrent spontaneous abortions.  Exp Clin Immunogenet . 1985;  2 137-139
  PubMedGoogle Scholar
• 63 Gleicher N. Autoantibodies in normal and abnormal pregnancy.  Am J Reprod Immunol . 1992;  28 269-273
  PubMedGoogle Scholar
• 64 Bjercke S. Recurrent abortions and lymphocyte transfusions.  Acta Obstet Gynecol Scand . 1994;  73 373-376
  PubMedGoogle Scholar
• 65 Agrawal S. Prevalence of MLR blocking antibodies before and after immunotherapy.  J Hematother Stem Cell Res . 2000;  9 257-262
  CrossrefPubMedGoogle Scholar
• 66 Takakuwa K. Result of immunotherapy on patients with unexplained recurrent abortion: a beneficial treatment for patients with negative blocking antibodies.  Am J Reprod Immunol . 1990;  23 37-41
  PubMedGoogle Scholar
• 67 Smith J B. Immunological studies in recurrent spontaneous abortion: effects of immunization of women with paternal mononuclear cells on lymphocytotoxic and mixed lymphocyte reaction blocking antibodies and correlation with sharing of HLA and pregnancy outcome.  J Reprod Immunol . 1988;  14 99-113
  PubMedGoogle Scholar
• 68 Pena R B. The production of MLR-blocking factors after lymphocyte immunotherapy for RSA does not predict the outcome of pregnancy.  Am J Reprod Immunol . 1998;  39 120-124
  PubMedGoogle Scholar
• 69 Raziel A. Intravenous immunoglobulin treatment of pregnant patients with unexplained recurrent abortions.  Hum Reprod . 1996;  11 711-715
  PubMedGoogle Scholar
• 70 Gleicher N. The worldwide collaborative observational study and multi-analysis in allogenic leukocyte immunotherapy for recurrent abortions.  Am J Reprod Immunol . 1994;  32 53-54
  PubMedGoogle Scholar
• 71 Coulam C B. Immunotherapy for recurrent pregnancy loss: analysis of results from clinical trials.  Am J Reprod Immunol . 1996;  35 352-359
  PubMedGoogle Scholar
• 72 Cotran R S. Inflammation and repair. In: Cotran RS, Robbins SL, Kumar V, eds. Robbins Pathologic Basis of Disease 5th ed. Philadelphia: WB Saunders 1994: 66-67
  Google Scholar
• 73 Holmes C H, Simpson K L. Complement in pregnancy, new insights into the immunobiology of the fetal-maternal relationship.  Immunology . 1993;  79 485-490
  PubMedGoogle Scholar
• 74 Holmes C H, Simpson K L, Wainwright S D. Preferential expression of the compliment regulatory protein decay accelerating factor at the fetomaternal interface during human pregnancy.  J Immunol . 1990;  144 3099-3105
  PubMedGoogle Scholar
• 75 Vanderpuye O A, Labarrere C A, McIntyre J A. The complement system in human reproduction.  Am J Reprod Immunol . 1992;  27 145-155
  PubMedGoogle Scholar
• 76 Holmes C H. Complement regulatory proteins at the feto-maternal interface during human placental development: distribution of CD-59 by comparison with membrane cofactor protein (CD46) and decay accelerating factor (CD55).  Eur J Immunol . 1992;  22 1579-1585
  PubMedGoogle Scholar
• 77 Holmes C H, Simpson, K L. Complement in pregnancy: new insights into the immunobiology of the fetal-maternal relationship.  Immunology . 1993;  79 485-490
  PubMedGoogle Scholar
• 78 Holmes C H. Complement and pregnancy: new insights into the immunobiology of the fetomaternal relationship.  Baillieres Clin Obstet Gynaecol . 1992;  6 439-460
  PubMedGoogle Scholar
• 79 Dekker G A. The immunology of preeclampsia.  Semin Perinatol . 1999;  23 24-33
  PubMedGoogle Scholar
• 80 Redman C W, Sacks G P, Sargent I L. Preeclampsia: an excessive maternal inflammatory response to pregnancy.  Am J Obstet Gynecol . 1999;  180 499-506
  CrossrefPubMedGoogle Scholar
• 81 Haeger M. Enhanced anaphlatoxin and terminal C5b-9 complement complex formation in patients with the syndrome of hemolysis, elevated liver enzymes, and low platelet count.  Obstet Gynecol . 1990;  76 698-702
  PubMedGoogle Scholar
• 82 Haeger M. Complement, neutrophil, and macrophage activation in women with severe preeclampsia and the syndrome of hemolysis, elevated liver enzymes, and low platelet count.  Obstet Gynecol . 1992;  79 19-26
  PubMedGoogle Scholar
• 83 Malan B I. Modulation of the humoral immune response by placental secretory factors.  Am J Reprod Immunol . 1996;  35 529-533
  PubMedGoogle Scholar
• 84 King A. The influence of the maternal uterine immune response on placentation in human subjects.  Proc Nutr Soc . 1999;  58 69-73
  CrossrefPubMedGoogle Scholar
• 85 Wegmann T G. Placental immunotropism: maternal T cells enhance placental growth and function.  Am J Reprod Immunol Microbiol . 1987;  15 67-69
  PubMedGoogle Scholar
• 86 Wegmann T G. The cytokine basis for cross-talk between the maternal immune and reproductive systems.  Curr Opin Immunol . 1990;  2 765-769
  CrossrefPubMedGoogle Scholar
• 87 Kilpatrick D C. Influence of human leukocyte antigen and tumour necrosis factor genes on the development of pre-eclampsia.  Hum Reprod Update . 1999;  5 94-102
  CrossrefPubMedGoogle Scholar
• 88 Arck P, Deitl J, Clark D. From the decidual cell internet: trophoblast-recognizing T cells.  Biol Reprod . 1999;  60 227-233
  PubMedGoogle Scholar
• 89 Bennet W A. First-trimester human chorionic villi express both immunoregulatory and inflammatory cytokines: a role for interleukin-10 in regulating the cytokine network of pregnancy.  Am J Reprod Immunol . 1999;  41 70-78
  PubMedGoogle Scholar
• 90 Hara N. Histochemical demonstration of interleukin-2 in decidua cells of patients with preeclampsia.  Am J Reprod Immunol . 1995;  34 44-51
  PubMedGoogle Scholar
• 91 Dudley D J. Hormonal pathways of preterm birth: immunoendocrinology of preterm labor, the link between corticotropin-releasing hormone and inflammation.  Am J Obstet Gynecol . 1999;  180 S251-256
  PubMedGoogle Scholar
• 92 Moreau P. IL-10 selectively induces HLA-G expression in human trophoblasts and monocytes.  Int Immunol . 1999;  11 803-811
  CrossrefPubMedGoogle Scholar
• 93 Szereday L, Varga P, Szeleres-Bartho J. Cytokine production by lymphocytes in pregnancy.  Am J Reprod Immunol . 1997;  38 418-422
  CrossrefPubMedGoogle Scholar
• 94 Semeniuk D J, Boismenu J, Tam J, Weissenhoefer W, Murgita R A. Evidence that immunosuppression is an intrinsic property of the alpha-fetoprotein molecule.  Adv Exp Med Biol . 1995;  383 255-269
  PubMedGoogle Scholar
• 95 Kauma S W. Placental Fas ligand expression is a mechanism for maternal immune tolerance to the fetus.  J Clin Endocrinol Metab . 1999;  84 2188-2194
  CrossrefPubMedGoogle Scholar
• 96 Guller S. The role of placental Fas ligand in maintaining immune privilege at maternal-fetal interfaces.  Semin Reprod Endocrinol . 1999;  17 39-44
  PubMedGoogle Scholar
• 97 Runic R. Apoptosis and Fas expression in human fetal membranes.  J Clin Endocrinol Metab . 1998;  83 660-666
  CrossrefPubMedGoogle Scholar
• 98 Hetts S W. To die or not to die: an overview of apoptosis and its role in disease.  JAMA . 1998;  297 300-307
  PubMedGoogle Scholar
• 99 Choi C. Fas ligand and Fas are expressed constitutively in human astrocytes and the expression increases with IL-1, IL-6, TNF-alpha, or IFN-gamma.  J Immunol . 1999;  162 1889-1895
  PubMedGoogle Scholar
• 100 O'Connell J. Expression of Fas (CD95/APO-1) ligand by human breast cancers: significance for tumor immune privilege.  Clin Diagn Lab Immunol . 1999;  6 457-463
  PubMedGoogle Scholar
• 101 Allaire A D, Ballenger K A, Wells S R, McMahon M J, Lessey B A. Placental apoptosis in preeclampsia.  Obstet Gynecol . 2000;  96 271-276
  CrossrefPubMedGoogle Scholar